Navigation Links
Freiburg scientist is awarded the Paul Ehrlich and Ludwig Darmstaedter Prize
Date:3/14/2014

This news release is available in German.

This news release is available in German.

Michael Reth has won the Paul Ehrlich and Ludwig Darmstaedter Prize, awarded by the Paul Ehrlich Foundation, for his research on the immune system. For the first time since 1996, the prize goes to a scientist working in Germany. Reth is Professor for Molecular Immunology at the Institute of Biology III of the University of Freiburg and Scientific Director of the Cluster of Excellence BIOSS, Centre for Biological Signalling Studies. He is also head of the department for Molecular Immunology at the Max Planck Institute of Immunobiology and Epigenetics (MPI-IE). The prize is endowed with 100,000 and is one of the highest honours in science in Germany. By awarding the prize to Reth, the Foundation has chosen to honour a scientist who, like Nobel laureate Paul Ehrlich, decodes how immunity operates at a molecular level, in order to find new therapies for cancer and infectious diseases.

"This award is a great honour for me, because I deeply admire Paul Ehrlich's work in immunology," Reth said. "He was one of the first scientists to consider the molecular level in this field." Following Ehrlich's scientific tradition, Reth chose to focus his research on how the human body recognises foreign substances.

"Due to the success of vaccinations, which was one of the greatest achievements in medicine, immunology has been an applied science from the beginning. However, we still do not fully understand the processes that underlie immunisation," Reth remarks. That is why his research revolves around the B cell component of the immune system. When activated, these blood cells produce antibodies to fight off infection. Reth investigates the structure and organisation of the B cell antigen receptors. These molecules on the surface of B cells recognise foreign substances, so-called antigens, and trigger the activation of the immune system. Reth was able to describe the basic structure of the antigen receptor of B cells for the first time in 1989. Together with his research group, he developed a new model for the activation of this receptor and recently provided further experimental evidence for this model.

Furthermore Reth has shown that receptors on the plasma membrane have a more complex structure than previously assumed. They are not freely diffusing on the cell surface but are organized in 50 to 150 nanometre sized membrane patches also called protein islands.

Reth is the third researcher from the Max Planck Institute of Immunobiology and Epigenetics to be awarded the Paul Ehrlich and Ludwig Darmstaedter Prize. Otto Lderitz (who won the prize in 1965) and Otto Westphal (who won in 1968), both directors at the Max Planck Institute in Freiburg, also received the award for their work on the structure and effect of bacterial toxins, or so-called lipopolysaccharides.


'/>"/>

Contact: Dr. Michael Reth
michael.reth@bioss.uni-freiburg.de
49-761-510-8420
Max-Planck-Gesellschaft
Source:Eurekalert  

Related biology news :

1. Plant biology discovery furthers scientists understanding of plant growth and development
2. Tropical grassy ecosystems under threat, scientists warn
3. Scientists herd cells in new approach to tissue engineering
4. Geoscientists to meet in Fayetteville to discuss triggered seismicity, karst & energy resources
5. SURA honors Georgia Tech biologist as Distinguished Scientist
6. Scientists discover the specific types of macrophages that affect Crohns disease severity
7. Scientists to tackle burden of cattle disease on UK farms
8. Scientists highlight the importance of nutrients for coral reefs
9. Scientists learn how pathogens hack our immune systems to go undetected
10. NPL scientists blend synthetic air to measure climate change
11. Southern insect scientists meeting in Greenville, S.C.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Freiburg scientist is awarded the Paul Ehrlich and Ludwig Darmstaedter Prize
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology: